Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
Toward personalized treatment in multiple myeloma based on molecular characteristics
C Pawlyn, FE Davies - Blood, The Journal of the American …, 2019 - ashpublications.org
To date, the choice of therapy for an individual multiple myeloma patient has been based on
clinical factors such as age and comorbidities. The widespread evolution, validation, and …
clinical factors such as age and comorbidities. The widespread evolution, validation, and …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an
important clinical challenge. However, the extent, origin, and drivers of ITH across cancer …
important clinical challenge. However, the extent, origin, and drivers of ITH across cancer …
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
The multiple myeloma (MM) genome is heterogeneous and evolves through preclinical and
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
B Oben, G Froyen, KH Maclachlan… - Nature …, 2021 - nature.com
Multiple myeloma (MM) is consistently preceded by precursor conditions recognized
clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering …
clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering …
Revealing the impact of structural variants in multiple myeloma
EH Rustad, VD Yellapantula, D Glodzik… - Blood cancer …, 2020 - AACR
The landscape of structural variants (SV) in multiple myeloma remains poorly understood.
Here, we performed comprehensive analysis of SVs in a large cohort of 752 patients with …
Here, we performed comprehensive analysis of SVs in a large cohort of 752 patients with …
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
Smoldering myeloma (SMM) is associated with a high-risk of progression to myeloma (MM).
We report the results of a study of 82 patients with both targeted sequencing that included a …
We report the results of a study of 82 patients with both targeted sequencing that included a …
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Patients with smoldering multiple myeloma (SMM) are observed until progression, but early
treatment may improve outcomes. We conducted a phase II trial of elotuzumab …
treatment may improve outcomes. We conducted a phase II trial of elotuzumab …
Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression
M Bustoros, R Sklavenitis-Pistofidis, J Park… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple
myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for …
myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for …